Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
89 hedge funds and large institutions have $226M invested in Poseida Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 28 increasing their positions, 16 reducing their positions, and 9 closing their positions.
947% more call options, than puts
Call options by funds: $1.26M | Put options by funds: $120K
233% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 9
75% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 16
62% more capital invested
Capital invested by funds: $140M → $226M (+$86.5M)
31% more funds holding
Funds holding: 68 → 89 (+21)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.83M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.64M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$2.34M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$1.67M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.2M |
| 2 |
PA
Perceptive Advisors
New York
|
-$2.65M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.48M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.44M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.06M |
PSTX Hedge Fund Activity: Q4 2022 in Review
89 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q4 2022, worth a combined $226M — up 62% from $140M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new PSTX positions and 9 closed out — a net gain of 21 holders — while 28 added to existing stakes and 16 trimmed.
The largest buyer was Millennium Management, adding an estimated $6.83M. The largest seller was Cormorant Asset Management, cutting an estimated $3.2M.
- 89 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q4 2022, up from 68 in Q3 2022.
- Funds reported $226M of Poseida Therapeutics, Inc. Common Stock stock for Q4 2022, up 62% quarter-over-quarter.
- 30 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q4 2022 and 9 closed out, a net change of +21 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q4 2022 was Millennium Management, an estimated $6.83M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q4 2022 was Cormorant Asset Management, an estimated $3.2M sold.
Based on aggregated 13F filings for Q4 2022.